At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions.
Enabling personalized cancer care
We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.
Oncobit’s PM platform is transforming melanoma management, empowering clinicians to monitor disease progression and treatment response closely and reliably to improve clinical management.
»
Prof. Dr. med. Reinhard Dummer
Professor at University Zürich, Skin Cancer Expert, Senior Medical Advisor at Oncobit
«
With Oncobit PM integrated into our existing digital PCR workflow, we can closely monitor ctDNA changes and gain deeper insights into each patient’s melanoma. Its standardized software ensures consistency, crucial for routine clinical use.
»
Prof. Dr. med. Christoffer Gebhardt
Medical Specialist in Dermatology, Deputy Clinical Director, University Medical Center Hamburg-Eppendorf – Dermatology and Venereology
«
Tracking ctDNA dynamics in uveal melanoma patients with Oncobit PM provides an important opportunity for oncologists to better monitor systemic therapy.
»
Prof. Dr. med. Jessica Hassel
Medical Specialist in Dermatology, Senior Physician, University Hospital Heidelberg
Our Journey
Oncobit Appoints Bram Goorden as Chairman
At its Annual General Meeting, Oncobit appointed Bram Goorden as Chairman of the Board, succeeding Dr. Ruedi Gygax after five years in the role. Dr. Gygax will continue to support the company as Board Advisor, while Prof. Mitch Levesque has stepped down from the Board and remains closely involved with Oncobit. The transition reflects Oncobit's continued growth and commercial expansion, including the recent launch of its first solution in the U.S. market and increasing collaborations with assay development and biopharma partners.
TrilliumBiO and Oncobit Launch Advanced Uveal Melanoma Monitoring Solution in the US
TrilliumBiO, a leader in biomarker discovery and precision diagnostics, and Oncobit, a Swiss precision oncology company, today announced the launch of Oncular™, making Oncobit’s uveal melanoma monitoring solution available in the US through TrilliumBiO’s multi-accredited laboratory.
Oncular™ brings Oncobit’s proprietary platform for personalized cancer monitoring to physicians across the US, enabling real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw.
We are pleased to announce the launch of a joint EADO–EUMelaReg project aimed at integrating circulating tumor DNA (ctDNA) into routine melanoma follow-up. The project will evaluate the clinical utility of ctDNA assessed using Oncobit’s CE-IVDR–marked digital PCR solution to detect relapse and to complement or potentially replace established monitoring approaches. By closely reflecting real-world clinical practice and leveraging the strengths of the EUMelaReg registry, this initiative seeks to advance precision monitoring in melanoma care.
This website uses cookies to provide the best possible functionality. We distinguish between functional cookies, which are necessary for the smooth functioning of the website, and optional cookies, which are used for marketing purposes.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
